6533b86ffe1ef96bd12cd4ad
RESEARCH PRODUCT
Gene transfer approaches for the treatment of inflammatory bowel disease.
Stefan WirtzMarkus F. Neurathsubject
Genetic enhancementGenetic VectorsGene ExpressionGene transferDiseaseInflammatory bowel diseaseAdenoviridaePathogenesisCrohn DiseaseIntestinal inflammationGeneticsMedicineAnimalsHumansMolecular BiologyMedical treatmentbusiness.industryBacterial InfectionsGenetic Therapymedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisIntestinesDisease Models AnimalImmunologyMolecular MedicineCytokinesColitis UlcerativeImmunotherapybusinessStem Cell Transplantationdescription
The pathogenesis of Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease, involves a complex interplay between certain genetic, environmental and immunological factors. Considerable research progress in the last decade defined key inflammatory pathways in the inflamed gut and identified new potential therapeutic targets. Since the current medical treatment with corticosteroids and anti-inflammatory drugs is often associated with undesired side effects and cannot completely cure IBD, these current advances in our understanding of intestinal pathology may now allow the development of new biologic treatment strategies including gene therapy. In this review, we will give a brief overview of potential gene therapy target molecules related to chronic intestinal inflammation. Furthermore, we summarize the results of recent preclinical studies for intestinal gene transfer and discuss future perspectives.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-05-01 | Gene therapy |